High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study

Am J Trop Med Hyg. 2015 Jul;93(1):73-5. doi: 10.4269/ajtmh.14-0810. Epub 2015 May 4.

Abstract

The World Health Organization recommends for tuberculosis retreatment a regimen of isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z), and streptomycin (S) for 2 months, followed by H, R, E, and Z for 1 month and H, R, and E for 5 months. Using data from the National Tuberculosis and Leprosy Program registry, this study determined the long-term outcome under programmatic conditions of patients who were prescribed the retreatment regimen in Kampala, Uganda, between 1997 and 2003. Patients were traced to determine their vital status; 62% (234/377) patients were found dead. Having ≤ 2 treatment courses and not completing retreatment were associated with mortality in adjusted analyses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antitubercular Agents / therapeutic use*
  • Coinfection
  • Ethambutol / therapeutic use
  • Female
  • Follow-Up Studies
  • HIV Infections / complications
  • Humans
  • Isoniazid / therapeutic use
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Pyrazinamide / therapeutic use
  • Recurrence
  • Retreatment
  • Retrospective Studies
  • Rifampin / therapeutic use
  • Streptomycin / therapeutic use
  • Survival Rate
  • Treatment Failure
  • Treatment Outcome
  • Tuberculosis / complications
  • Tuberculosis / drug therapy*
  • Tuberculosis / mortality
  • Uganda

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Ethambutol
  • Isoniazid
  • Rifampin
  • Streptomycin